Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses ways to increase provider comfort with biosimilars.
Transcript
The other thing to add is probably the knowledge-sharing between practitioners with those who have used biosimilars already. I think, a lot of times, people are waiting to see how their peers have utilized the product, how successful they’ve been. So having that real-world evidence and best-practice sharing is going to help a lot as well.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.